EyeGate is developing and commercializing products for treating diseases and disorders of the eye. The Company’s products are based on two proprietary platform technologies:

EyeGate’s first platform is based on a cross-linked thiolated carboxymethyl hyaluronic acid (“CMHA-S”), a modified form of the natural polymer hyaluronic acid (“HA”), which is a gel that possesses unique physical and chemical properties including hydration and healing when applied to the ocular surface. The ability of CMHA-S to protect and adhere longer to the ocular surface, and resist degradation makes it well-suited for treating various ocular surface injuries.

EGP-437, EyeGate’s second product in clinical trials, incorporates a reformulated topically active corticosteroid, Dexamethasone Phosphate that is delivered into the ocular tissues through EyeGate’s proprietary innovative drug delivery system, the EyeGate II Delivery System. EGP-437 is currently in trials for the treatment of uveitis and pain and inflammation following cataract surgery. EyeGate has granted a subsidiary of Valeant Pharmaceuticals an exclusive worldwide license to the product in these indications.

Stock Quote

EYEG (Common Stock)
  • ExchangeNASDAQ
  • Price$5.54
  • Change-0.52
  • Volume85085
  • Data as of Feb 26, 2021 4:00PM